Is Stronger Guidance and CHOPIN Data Changing the Investment Case for Delcath Systems (DCTH)? [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
million from its CHEMOSAT and HEPZATO KIT products, as well as positive results from the CHOPIN Phase 2 trial showing significantly improved progression-free survival for metastatic uveal melanoma patients. This news highlights the company's momentum in expanding the clinical utility of its platform and underscores a strong financial position, including positive cash flow and no debt. We'll assess how the significant improvement in progression-free survival reported in the CHOPIN trial shapes Delcath's investment narrative. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. Delcath Systems Investment Narrative Recap To be a Delcath Systems shareholder, one needs to believe that the company can maintain momentum in commercializing HEPZATO and CHEMOSAT despite ongoing pricing pressures and the risk that adoption could s
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Investors in Delcath Systems (NASDAQ:DCTH) have seen splendid returns of 221% over the past three years [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal MelanomaBusiness Wire
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems (NASDAQ:DCTH) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program [Yahoo! Finance]Yahoo! Finance
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Sec Filings
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- 11/13/25 - Form 4
- DCTH's page on the SEC website